Skip to main content

Advertisement

SpringerLink
Log in

Bone

Fracture risk in the JUPITER trial—statin treatment or not?

  • News & Views
  • Published:

From Nature Reviews Endocrinology

View current issue Sign up to alerts

Observational studies suggest that statin treatment has a fracture-preventive effect; however, there is only limited supporting evidence from randomized controlled trials. Now, results from the JUPITER trial show that rosuvastatin treatment does not reduce the risk of fractures and, further, that levels of high sensitivity C-reactive protein are not associated with fracture risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Toh, S. & Hernández-Díaz, S. Statins and fracture risk. A systematic review. Pharmacoepidemiol. Drug Saf. 16, 627–640 (2007).

    Article  CAS  Google Scholar 

  2. Peña, J. M. et al. Statin therapy and risk of fracture: results from the JUPITER randomized clinical trial. JAMA Intern. Med. http://dx.doi.org/10.1001/jamainternmed.2014.6388.

  3. Vestergaard, P., Rejnmark, L. & Mosekilde, L. Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark. Osteoporosis Int. 16, 134–141 (2005).

    Article  Google Scholar 

  4. Rejnmark, L., Vestergaard, P. & Mosekilde, L. Statin but not non-statin lipid-lowering drugs decrease fracture risk: a nation-wide case–control study. Calcif. Tissue Int. 79, 27–36 (2006).

    Article  CAS  Google Scholar 

  5. Zhang, J. et al. LRP8 mediates Wnt/β-catenin signaling and controls osteoblast differentiation. J. Bone Miner. Res. 27, 2065–2074 (2012).

    Article  CAS  Google Scholar 

  6. Beisiegel, U., Weber, W., Ihrke, G., Herz, J. & Stanley, K. K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 341, 162–164 (1989).

    Article  CAS  Google Scholar 

  7. Ridker, P. M. et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 373, 1175–1182 (2009).

    Article  CAS  Google Scholar 

  8. Berglundh, S., Malmgren, L., Luthman, H., McGuigan, F. & Akesson, K. C-reactive protein, bone loss, fracture, and mortality in elderly women: a longitudinal study in the OPRA cohort. Osteoporos Int. http://dx.doi.org/10.1007/s00198-014-2951-7.

  9. Grady, D. et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288, 49–57 (2002).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Clinical Medicine and Endocrinology, Aalborg University Hospital, Mølleparkvej 4, DK-9100, Aalborg, Denmark

    Peter Vestergaard

Authors
  1. Peter Vestergaard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Vestergaard.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vestergaard, P. Fracture risk in the JUPITER trial—statin treatment or not?. Nat Rev Endocrinol 11, 135–136 (2015). https://doi.org/10.1038/nrendo.2014.232

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrendo.2014.232

  • Springer Nature Limited

This article is cited by

Search

Navigation